Sacubitril/Valsartan Curbs Cardiotoxicity From Chemotherapy

Published Date: 22 Nov 2024

Benefit shown in trial of patients flagged for high risk of cardiotoxicity

Read Full News

Latest News

Lentigo Maligna Rarely Progresses Despite Rising Incidence

Despite rising cases in recent years, lentigo maligna shows minimal progression to melanoma, and patients with this condition are more likely to die due to other factors, a retrospective study finds.

Baxdrostat Approval May Open Doors for HTN Therapy

The FDA’s recent approval of baxdrostat may usher in new possibilities for treatment for uncontrolled hypertension.

Eating for One: The Future of Personalized Nutrition

Nutrition science is closing in on truly personalized dietary advice. The bigger challenge? Making sure it does not only land on wealthy plates.

When the Defibrillator Stays in Its Box

After teenage footballer Adam Ankers died in cardiac arrest while a defibrillator sat unused on the pitch, 13 organisations now have until June to respond to a coroner's report.

Is Hypertension Undertreated in Pediatrics?

Long-term implications may be underestimated, and new data show relatively low medication use.

Prior Auth Rules Vary Widely Across Insurers, Study Finds

A new study finds that prior authorization requirements vary widely across major insurers and suggests large language models could help streamline how authorization rules are interpreted and processed.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Despite rising cases in recent years, lentigo maligna shows minimal progression to melanoma, and patients with this condition are more likely to die due to other factors, a retrospective study finds.

The FDA’s recent approval of baxdrostat may usher in new possibilities for treatment for uncontrolled hypertension.

Nutrition science is closing in on truly personalized dietary advice. The bigger challenge? Making sure it does not only land on wealthy plates.

After teenage footballer Adam Ankers died in cardiac arrest while a defibrillator sat unused on the pitch, 13 organisations now have until June to respond to a coroner's report.

Long-term implications may be underestimated, and new data show relatively low medication use.

A new study finds that prior authorization requirements vary widely across major insurers and suggests large language models could help streamline how authorization rules are interpreted and processed.

News All Time

How Lifeline Brought the AMR Crisis to the London Stage

Real doctors joined the London cast of Lifeline the Musical to bring the growing threat of antimicrobial resistance to wider audiences.

Cardiorenal Benefits of GLP-1s Found in Type 1 Diabetes

A large database study shows lower risk for major adverse cardiovascular events and end-stage kidney disease, with no increase in adverse events.

Germany Flags Safety Risks in ‘Vitamin Drip’ Trend

BfArM warns ‘vitamin drips’ can cause hypervitaminosis, electrolyte imbalance, allergic reactions up to anaphylaxis, fluid overload, and IV complications such as air embolism.

Arterial Widening, Not Blockage, Tied to Common Stroke

Arterial widening, not vessel blockage, is strongly associated with lacunar stroke, a finding that could explain why conventional antiplatelet therapies offer limited benefit.

Single-Pill Hypertension Therapy Remains Underutilized

Single-pill combination therapy remains underused as the initial treatment for adults newly diagnosed with hypertension, despite repeated guideline recommendations.

Maternal Diabetes in Pregnancy Tied to CVD Risk in Children

Maternal diabetes during pregnancy is associated with an increased risk for cardiovascular disease in offspring, and part of this association is explained by birth complications.

Polycystic Ovary Syndrome Demands Multidisciplinary Approach

Along with endocrinologists, ob/gyns, mental health professionals, and nutritionists, dermatologists play a key role in addressing polycystic ovary syndrome, experts say.

Time in Target Range Metric May Aid in CKD Management

The urine albumin/creatinine ratio time in target range predicts cardiovascular outcomes in people with and without chronic kidney disease.

SSRI vs NDRI: Which Is Better for Post-Stroke Depression?

Bupropion is linked to lower suicidal ideation risk but higher odds of demoralization and apathy vs fluoxetine in post-stroke depression, new research shows.

TADV Saves Limbs in No-Option CLTI Patients

More than 80% of no-option chronic limb-threatening ischemia patients avoided amputation for 6 months after the procedure while enjoying improved wound healing and reduced pain.

Underground Hospitals: Is Combat Medicine Entering a New Era?

Ukrainian clinicians increasingly rely on protected underground facilities as drone threats complicate evacuation and strain traditional battlefield treatment models.

France Focuses on Drugs That Raise Fall Risk in Older Adults

Long-term benzodiazepines and anticholinergics drive falls in seniors; prioritize nonpharmacologic care and deprescribing to cut injuries and hospitalizations.

Uraemic Marker Predicts Mortality After Kidney Transplant

Plasma levels of symmetric dimethylarginine are independently associated with an increased risk for mortality in adult kidney transplant recipients, a prospective study finds.

GLP-1 Drugs Tied to Cardiovascular Benefits in T1D

Adults with T1D who receive GLP-1-based therapy may have a lower risk for adverse cardiovascular outcomes and no significant increase in diabetic ketoacidosis compared with those who do not.

Transient Neurologic Symptoms: What Clinicians Miss

Speakers warn that transient neurologic events may conceal high-risk vascular disease, seizures, or amnestic syndromes requiring rapid evaluation.

SGLT2 Inhibitors Show Similar Cardiorenal Benefits

Empagliflozin and dapagliflozin show similar effectiveness in preventing cardiorenal outcomes among patients with type 2 diabetes without prior cardiovascular or renal disease.